The new WHO classification abolishes the barrier between RAEB-t and the acute erythroleukaemias with multilineage dysplasia by lowering to 20% the number of blasts required for the definition of leukaemia. 3 Erythroleukaemia is preceded by a myelodysplastic syndrome in 40% of patients. 4 Multilineage dysplasia is present in 70% of erythroleukaemia. 5 Abnormalities of chromosomes 5 and 7 were found in 65% of erythroleukaemia and this frequency is as high as the frequency found in myelodysplastic syndromes. Thus the differential diagnosis between RAEB-t and AML6 is often difficult because of the overlapping features between myelodysplastic syndrome with excess of erythroblasts and erythroleukaemia.
Our objectives were: (1) to compare RAEB-t and AML6 by their cytologic, karyotypic and evolutive characteristics; and (2) to study the prognostic role of the percentage of erythroblasts in RAEB-t by comparing RAEB-t with less than 50% of erythroblasts and RAEB-t with more than 50% of erythroblasts.
The diagnosis was based on cytologic examination of sternal punction slides of three centres between January 1985 and June 2002: we selected typical AML6 defined by FAB 1985 classification, RAEB-t (with more than 50% of erythroblasts and with less than 50% of erythroblasts). The number of blasts was calculated on the remaining cell population after the withdrawal of the erythroid lineage in RAEB-t with more than 50% of erythroblasts and AML6. The cytology of abnormal cells was described: erythroid dysplasia (macroblasts, basophilic stipplings, lamellar cytoplasm, multinuclearity, caryorrhexis); myeloid dysplasia (hypogranulation, abnormalities of nucleus segmentation); and megakaryocyte dysplasia (hyposegmentation of nuclei, micromegakaryoblasts).
The karyotypes were classified into three groups of risk as defined by the MRC AML10 classification: 6 The study reported on 46 patients with the following repartition (Table 1) : 23 AML6, 23 RAEB-t (14 RAEB-t 450% of erythroblasts, nine RAEB-t o50% of erythroblasts); the average age was 65.84 years (range 20-91 years). Myelodysplastic syndromes (RAEB-t) were older than patients having an AML6 (MDS ¼ 65 vs AML6 ¼ 48 years, Po0.005). There was a male preponderance (60%). In all, 18 patients (35%) have been exposed to carcinogenic products. More than half (65%) of the patients having an AML6 had a chemotherapy or a professional exposure, while this proportion reached 34% of patients having a myelodysplastic syndrome (P ¼ 0.038). Of 20 exposed patients, 13 had chemotherapy, radiotherapy or immunosuppressor-like azathioprine. The delay between the exposure to toxics and the disease was identical in the different groups (average ¼ 3478 months).
All patients were admitted for anaemia (median hemoglobin: 8.6 g/dl). There was no significant difference between myelodysplastic syndromes and AML6 for the degree of anaemia. The average number of peripheral erythroblasts were 22%. Only one patient had a hepatosplenomegaly.
On trephine biopsy, the average number of erythroblasts was 26% for RAEB-t o50% of erythroblasts, 61% for RAEB-t 450% of erythroblasts and 59% for AML6. The average number of blasts was 23, 30 and 36%, respectively, for RAEB-t o50% of erythroblasts, RAEB-t 450% of erythroblasts and AML6. In all, 64% of RAEB-t and 100% AML6 had a dyserythropoiesis. The percentage of dysmyelopoiesis and dysmegakaryopoiesis was similar in the three groups. All patients had at least two-lineage dysplasia.
The karyotypes were distributed into three groups according to the MRC classification: good (n ¼ 1), intermediate (n ¼ 20) and bad prognosis groups (n ¼ 16). While the repartition of intermediate prognosis karyotypes were not statistically different between RAEB-t and AML6 (48 vs 35%), there were more bad prognosis karyotypes in AML6 (52%) than in RAEB-t (26%) (w 2 test, Po0.05). Patients (43%) had a karyotype involving the chromosomes 5 or 7. The complete remission (CR) rate in intermediate risk karyotype was 47 vs 31% in bad risk karyotype (NS).
More than 50% (n ¼ 30) of patients received a chemotherapy (induction with anthracycline 5 days and cytarabine 7 days, and consolidation with cytarabine). The CR rate was 53% (58% for RAEB-t and 35% for AML6, NS). Patients (81%) relapsed with a median time of 975 months. Three patients were allotransplanted. Two of these three patients are still alive with a maximal follow-up of 59 months. The third patient, who died of disease, did not have a CR before BMT.
We found neither significant difference in terms of survival between AML6 and RAEB-t (Figure 1 , log-rank test, NS) nor difference between RAEB-t 450% of erythroblasts and RAEB-t o50% of erythroblasts (9 months for AML6 vs 16 months for RAEB-t 450% of erythroblasts and 5 month for RAEB-t o50% of erythroblasts, Figure 2 , log-rank test, NS). Patients having a complex karyotype had a shorter median survival (6 months) than patients having an intermediate prognosis karyotype (14 months) (Figure 3 , Po0.025).
We have shown that RAEB-t have the same cytological and survival characteristics as AML6. This study warrants the WHO classification that lowered the threshold of the blasts to 20% to define AML.
Kowal-Vern suggests that the number of proerythroblasts is a pejorative prognosis factor. 8 In his study, AML6 patients were divided into three groups: M6A with more than 30% of blasts and less than 30% of proerythroblasts (/total of erythroid cells); M6B with less than 30% of blasts and more than 30% of proerythroblasts; and M6C with more than 30% of blasts and more than 30% of proerythroblasts. The median survival of each group was, respectively, of 31, 3and 10 months. In our study, 21 patients entered the criteria of M6A and the median survival of our group is shorter than Kowal-Vern's group (10 vs 25 months). It was probably explained by the fact that in our AML6A group, there were only two normal karyotypes, while in Kowel-Vern's study half of M6a had a normal karyotype. This discrepancy suggests that karyotype is a more important prognosis factor than the number of proerythroblasts. In our study, the percentage of erythroblasts or the percentage of blasts did not influence the overall survival.
Our patients with AML6 had erythroid dysplasia in 100% of cases. All patients had a bilineage dysplasia. RAEB-t and AML6 had the same cytological characteristics with the same degree of dysplasia in the erythroid, myeloid and megakacaryocyte lineage, respectively. We can wonder as to whether AML6 defined currently by the FAB would be the new entity AML with multilineage dysplasia defined by the WHO classification. The aspect of trilineage dysplasia was frequent in our AML6 patients 
Figure 1
Comparison between overall survival in AML6 and RAEB-t.
Figure 2
Comparison between overall survival in AML6, RAEB-t o50% ERB and RAEB-t 450% ERB. with more than 70% of patients having dysgranulopoiesis and dysmegakaryopoiesis. This frequency is clearly higher than the frequency of AML trilineage among AML de novo. Trilineage dysplasia does not influence the rate of remission after chemotherapy. On the other hand, this trilineage dysplasia is correlated with cytogenetic abnormalities favoring the expansion of dysplastic clones.
We confirm that karyotype is a potent prognostic factor in high-grade MDS and AML6 (median survival of 6 months for the high-risk group vs 14 months for the intermediate risk group). In our AML6 study, we found chromosomic abnormalities such as alterations of chromosomes 5 and 7 in six out of 17 karyotypes (35%). In secondary AML, the incidence of these karyotype abnormalities was 10-15%. In myelodysplastic syndromes, the deletion of the long arm of the chromosome 5 is more frequent (40-60%). In the literature, losses of material on the chromosome 7 have an incidence of 30% in RAEB and RAEB-t. In our study, chromosome 7 mutations were found in 26% of AML6 and 24% of RAEB-t. Patients (67%) having chromosomes 5 and 7 abnormalities had received chemotherapy for a haematologic or solid neoplasia, or an exposure to professional mutagenic agents in our study.
The long-term survivors of our study received allogeneic bone marrow tranplantation. Bone marrow transplantation could improve event-free survival of AML6. A therapeutic decisional tree according to the age, the degree of dysplasia, the cytogenetics and not the number of erythroblasts and blasts myeloids would be more adequate. As of the high median age, the nonmyeloablative allogeneic stem cell transplantation should be evaluated in this pathology. 
